Clinical, Electrophysiological and E-field Modelling Evidence of High Density Transcranial Direct Current Stimulation in Motor Stroke (E-brain)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Stroke cause direct network dysfunctions correlating with the underlying behavioral deficits In that context, characterize and boost neuronal reshaping towards a favorable state for recovery has become a distinguished therapeutic approach. Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation able to locally modulate neuronal activity and modify neural arquitecture.
In such scenario, the investigators develop in this protocol a new tDCS multitarget fronto-cerebellar tDCS approach, exploring the benefits of boosting motor dysfunctions by means of a dual site-approach, up-regulating dlPFC and CB activity. The investigators here design a pilot experimental clinical trial exploring the accumulative clinical potential for motor skill & learning recovery and EEG effects of a high-density bifocal transcranial direct current stimulation protocol (HD-tDCS).
The investigators hypothesize that the tDCS protocol will promote direct functional motor reorganization helping relearning motor process, will boost the activity of prefrontal settled systems correcting attentional deficits and increasing strength connectivity with premotor systems, and will normalize large-scale abnormalities increasing interhemispheric functional connectivity (i.e., functional integration), decreasing interhemispheric asymmetry (i.e., functional segregation) and restoring transcallosal balance, impacting positively either in motor and cognitive recovery. All in all, this study will be the first exploring the simultaneous modulation of two different targets in stroke population corresponding to different networks looking for a summative/synergistic effects helping motor and cognitive functions recovery.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Maria Teresa Colomina Fosch, MD, PhD
- Phone Number: +34977558153
- Email: mariateresa.colomina@urv.cat
Study Locations
-
-
Cataluña
-
Tarragona, Cataluña, Spain, 43007
- Recruiting
- University Hospital Joan XXIII
-
Contact:
- Maria Teresa Colomina Fosch, MD, PhD
- Phone Number: +34977558153
- Email: mariateresa.colomina@urv.cat
-
Principal Investigator:
- Xavier Corominas, MsC
-
Sub-Investigator:
- Martina Bracco, PhD
-
Sub-Investigator:
- Montse Fibla, PhD
-
Sub-Investigator:
- Rosa Maria San Segundo, MD
-
Sub-Investigator:
- Maria Teresa Colomina, MD, PhD
-
Sub-Investigator:
- Antoni Valero-Cabré, MD,PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Received a diagnosis of supratentorial ischemic or hemorrhagic stroke confirmed by neuroimage (MRI, PET, CT, fMRI or DTI) in the middle cerebral artery territory or encompassing fronto-temporo-parietal hemorrhages
- Enrolled in a live rehabilitation program in the rehabilitation and physical medicine department
- Between 4 and 12 months after stroke episode
- Have signed the informed form
Exclusion Criteria:
- Medical instability with the presence of infections, assisted ventilation, epilepsy or recurrent seizures, untreated psychiatric disorders or an active treatment with sedative drugs
- tDCS contraindications as defined by the international safety guidelines
- Large aphasic, psychiatric and cognitive deficits limiting patient's comprehension
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Prefrontal stimulation.
Participants receive anodal tDCS on the ipsilesional dlPFC for 5days/week for 2 weeks.
|
Non-invasive brain stimulation neuromodulation using HD (3,14cm^2) gel based round electrodes. Scalp electrode locations will be positioned based on a optimized biophysical solution targeting ipsilesional dlPFC and the contralesional anterior cerebellum. Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 1.73mA. Patients in the cerebellar stimulation group will receive 20 min of HD-tDCS with 2.0mA. Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 3.73 mA. Patients in the sham stimulation group will receive 20 min of sham HD-tDCS, with 30 seconds ramp-up and 30 seconds ramp-down. |
|
Experimental: Cerebellar stimulation.
Participants receive anodal tDCS on the contralesional cerebellum for 5days/week for 2 weeks.
min of HD-tDCS with 2.0mA.
|
Non-invasive brain stimulation neuromodulation using HD (3,14cm^2) gel based round electrodes. Scalp electrode locations will be positioned based on a optimized biophysical solution targeting ipsilesional dlPFC and the contralesional anterior cerebellum. Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 1.73mA. Patients in the cerebellar stimulation group will receive 20 min of HD-tDCS with 2.0mA. Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 3.73 mA. Patients in the sham stimulation group will receive 20 min of sham HD-tDCS, with 30 seconds ramp-up and 30 seconds ramp-down. |
|
Experimental: Fronto-cerebellar stimulation.
Participants receive simultaneous anodal tDCS on the ipsilesional dlPFC and in contralesional cerebellum for 5days/week for 2 weeks.
|
Non-invasive brain stimulation neuromodulation using HD (3,14cm^2) gel based round electrodes. Scalp electrode locations will be positioned based on a optimized biophysical solution targeting ipsilesional dlPFC and the contralesional anterior cerebellum. Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 1.73mA. Patients in the cerebellar stimulation group will receive 20 min of HD-tDCS with 2.0mA. Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 3.73 mA. Patients in the sham stimulation group will receive 20 min of sham HD-tDCS, with 30 seconds ramp-up and 30 seconds ramp-down. |
|
Sham Comparator: Sham stimulation.
Participants receive sham tDCS for 5days/week for 2 weeks.
|
Non-invasive brain stimulation neuromodulation using HD (3,14cm^2) gel based round electrodes. Scalp electrode locations will be positioned based on a optimized biophysical solution targeting ipsilesional dlPFC and the contralesional anterior cerebellum. Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 1.73mA. Patients in the cerebellar stimulation group will receive 20 min of HD-tDCS with 2.0mA. Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 3.73 mA. Patients in the sham stimulation group will receive 20 min of sham HD-tDCS, with 30 seconds ramp-up and 30 seconds ramp-down. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pre-to-post intervention change on motor skills. To measure such domain, the Fugl-Meyer assessment (FMA) will be used.
Time Frame: Baseline (W0) 3 days pre-intevention onset, post-intervention (W3) 3 days post-intervention finalization, and 30 days (W7) post-intervention finalization.
|
The Fugl Meyer is a widely used scale to asses motor impairment on post-stroke patients and is considered one of the most comprehensive and reliable quantitative measures for motor hemiplegic dysfunctions 61.
The FMA provides an incapacity index divided in five sub-scales encompassing the assessment of functional motricity, sensibility, balance, joint range and joint pain.
Among the sub-sections of the scale, we will only use the functional motricity assessment to evaluate the motor domain, including the upper extremity (FMA-UE) and the lower extremity (FMA-LE).
The FMA-UE and FMA-LE include a series of items measuring movement, coordination and reflexes.
|
Baseline (W0) 3 days pre-intevention onset, post-intervention (W3) 3 days post-intervention finalization, and 30 days (W7) post-intervention finalization.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pre-to-post intervention change on motor adaptation skills. To measure such domain, a computer-based visuo-motor task will be used.
Time Frame: Baseline (W0) 3 days pre-intevention onset, post-intervention (W3) 3 days post-intervention finalization, and 30 days (W7) post-intervention finalization.
|
The visuo-motor task is a computer task classically used to explore the human motor underpinnings of error control, skill learning, acquisition and/or adaptation.
In the task, participants are instructed to control a cursor displayed in the computer's screen be means of a joystick handled with the impaired limb.
A series of consecutive trials exploring motor adaptation to external perturbations are conducted.
In order to quantify the motor performance adaptation from the visuo-motor task, the mean angular trajectory error ("MeanSumErr"; cm) at peak tangential velocity (PV),will be the selected output to represent subjects performance, where lower punctuations will correspond to better motor adaptation.
|
Baseline (W0) 3 days pre-intevention onset, post-intervention (W3) 3 days post-intervention finalization, and 30 days (W7) post-intervention finalization.
|
|
Pre-to-post intervention change on cognitive abilities.To measure such domain. the AX-continuous performance task (AX-CPT) will be used.
Time Frame: Baseline (W0) 3 days pre-intevention onset, post-intervention (W3) 3 days post-intervention finalization, and 30 days (W7) post-intervention finalization.
|
The AX-CPT is a computer paradigm classically used to explore sustained attention and cognitive control where its performance can be correlated with the impairment level in neurological conditions.
In the AX-CPT participants are required to be aware to a serial continuous presentation of letters giving a target response.
Participants are instructed to provide a correct response each time the cue-probe letter combination A + X is presented.
Otherwise, participants are instructed to provide an alternative response when any other cue-probe letter combination is presented (e.g., A + S, etc.).In order to quantify attention performance from the AX-CPT task, the total number of errors will be the outcome used to represent sustained attention impairment.
|
Baseline (W0) 3 days pre-intevention onset, post-intervention (W3) 3 days post-intervention finalization, and 30 days (W7) post-intervention finalization.
|
|
Pre-to-post intervention change on cognitive abilities. To measure such domain the Montreal cognitive assessment (MoCA) will be used.
Time Frame: Baseline (W0) 3 days pre-intevention onset, post-intervention (W3) 3 days post-intervention finalization, and 30 days (W7) post-intervention finalization.
|
The Montreal cognitive assessment (MoCA) is a quantitative screening tool used to explore stroke related cognitive deficits.
The MoCA test is composed by a series of questions and tasks specifically designed to assess visuospatial functions, executive functions, working memory and short-term memory, attention, concentration, language and orientation.
In order to quantify global pre-to-post intervention change in the cognitive impairment, the total summed punctuations will be used.
|
Baseline (W0) 3 days pre-intevention onset, post-intervention (W3) 3 days post-intervention finalization, and 30 days (W7) post-intervention finalization.
|
|
Pre-to-post intervention change on global stroke impairment. To measure such domain the National institutes of health stroke scale (NIHSS) will be used.
Time Frame: Baseline (W0) 3 days pre-intevention onset, post-intervention (W3) 3 days post-intervention finalization, and 30 days (W7) post-intervention finalization.
|
The NIHSS is a quantitative scale of stroke related neurologic deficits widely used to characterize baseline impairment in clinical trials.
The NIHSS scale is a neurologic examination exploring consciousness level, visual field, language, hemineglect, hemiplegia, movement disorders and sensory domains.
In order to represent global stroke severity impairment, the total summed punctuations will be used.
|
Baseline (W0) 3 days pre-intevention onset, post-intervention (W3) 3 days post-intervention finalization, and 30 days (W7) post-intervention finalization.
|
|
Pre-to-post intervention change on neglect impairment. To measure such domain, the letter cancelation test, the bell cancelation test and the line bisection test will be used.
Time Frame: Baseline (W0) 3 days pre-intevention onset, post-intervention (W3) 3 days post-intervention finalization, and 30 days (W7) post-intervention finalization.
|
The letter cancelation test quantifies the presence of visual neglect scanning deficits.
The bells cancelation test quantifies visual neglect deficits in the extra personal space.
The line bisection test quantifies spatial neglect deficits.In order to quantify visual deficits from the letter cancelation test, bells cancelation test, and line bisection test, the total number of marked letters, the total number of marked bells and the deviation percentage of the patient's mark from the actual center of the line will be the outcomes used to represent the test performance.
Each outcome will be reported and analyzed by isolate.
|
Baseline (W0) 3 days pre-intevention onset, post-intervention (W3) 3 days post-intervention finalization, and 30 days (W7) post-intervention finalization.
|
|
Pre-to-post intervention modualtion of resting-state and task-engaged power spectral frequency, functional connectivity and entropy. To measure such domains, a electroencephalography (EEG) analysis will be conducted.
Time Frame: Baseline (W0) 3 days pre-intevention onset, post-intervention (W3) 3 days post-intervention finalization, and 30 days (W7) post-intervention finalization.
|
EEG data will be used to capturethe neural response to different HD-tDCS stimulation among our intervented groups.Data will be analyzed exploring mean power spectrum variations, exploring interhemispheric asymmetry by means of the pairwise derived Brain Symmetry Index, exploring functional connectivity modulation by means of the imaginary part of coherency and deep matrix comparisons, and exploring the variations on signal's complexity by means of a modified multi-scale entropy method.
Each analysis will be conducted and explored in isolate.
|
Baseline (W0) 3 days pre-intevention onset, post-intervention (W3) 3 days post-intervention finalization, and 30 days (W7) post-intervention finalization.
|
|
Correlations between the electric field impact and the changes in the behavioral outcomes (clinical outcomes and eeg response). To perform such correlations, individual simulated biophysical models of electric stimulation distribution will be conducted.
Time Frame: MRI will be acquired 2 weeks before treatment onset or from the medical database.
|
First, we will reconstruct T1-weighted MRI individual head models.
Following simulations of the received stimualtion protocol will be conducted in every single subject to explore the real impact of the stimulation.
Different components of the electric field will be extracted and correlated with the behavioral results.
|
MRI will be acquired 2 weeks before treatment onset or from the medical database.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 077/2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.